AtaiBeckley Inc. (NASDAQ:ATAI) is one of them The best low-cost stocks to buy for under $5. On March 3, Atay Beckley announced a successful Phase 2 meeting with the FDA on BPL-003, a proprietary formulation of mebofotenine benzoate for treatment-resistant depression/TRD. The FDA indicated support for the proposed Phase 3 program, providing constructive feedback on the design and safety database requirements for this long-term indication.
These milestones follow a breakthrough therapy designation granted in late 2025, and the company remains on track to launch a Phase 3 program in the second quarter of 2026. The Phase 3 program consists of two parallel pivotal studies, ReConnection 1 and ReConnection 2, followed by 52-52 long-term and safety-related studies. Individual retreat. ReConnection 1 will evaluate single doses of 8 mg and 4 mg versus placebo to determine dose-response relationships, while ReConnection 2 will investigate a two-dose induction model at days 1 and 15.
Designed to fit into existing interventional psychotherapy workflows, BPL-003 aims to provide a rapid and sustainable treatment option with approximately two hours of in-clinic experience. AtaiBeckley Inc. (NASDAQ:ATAI) believes this model addresses significant barriers to patients and providers requiring only a few treatments per year.
AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company that researches, develops, and commercializes mental health treatments in the United States, Germany and Canada.
While we accept ATAI’s potential as an investment, we believe some AI stocks offer higher potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: The 40 most popular stocks among hedge funds heading into 2026 and the 12 most promising microcap stocks, according to analysts.
Disclosure: None. Follow the inside port on Google News.
